Novartis logo
NOVN logo

NovartisSWX:NOVN Stock Report

Market Cap CHF 194.7b
Share Price
n/a
1Y11.1%
7D4.2%
Portfolio Value
​
View

Novartis AG

SWX:NOVN Stock Report

Market Cap: CHF 194.7b

NOVN Stock Overview

Engages in the research, development, manufacture, distribution, marketing, and sale of pharmaceutical medicines in Switzerland and internationally. More details

NOVN fundamental analysis
Snowflake Score
Valuation5/6
Future Growth2/6
Past Performance6/6
Financial Health5/6
Dividends5/6

Rewards

Trading at 62.9% below our estimate of its fair value

Earnings are forecast to grow 7.31% per year

Earnings grew by 39.4% over the past year

Pays a reliable dividend of 3.55%

Trading at good value compared to peers and industry

Risk Analysis

No risks detected for NOVN from our risk checks.

My Notes

Capture your thoughts, links and company narrative

Novartis AG Competitors

Roche Holding

SWX:ROG

CHF 233.9b

Dottikon ES Holding

SWX:DESN

CHF 3.0b

Cosmo Pharmaceuticals

SWX:COPN

CHF 1.0b

Lonza Group

SWX:LONN

CHF 44.3b

Price History & Performance

Summary of share price highs, lows and changes for Novartis
Historical stock prices
Current Share PriceCHF 97.71
52 Week HighCHF 102.72
52 Week LowCHF 83.63
Beta0.53
1 Month Change8.10%
3 Month Change5.22%
1 Year Change11.07%
3 Year Change21.91%
5 Year Change1.97%
Change since IPO162.66%

Recent News & Updates

Novartis (VTX:NOVN) Is Increasing Its Dividend To $3.50

Feb 04
Novartis (VTX:NOVN) Is Increasing Its Dividend To $3.50

Novartis (VTX:NOVN) Has A Rock Solid Balance Sheet

Dec 17
Novartis (VTX:NOVN) Has A Rock Solid Balance Sheet

Recent updates

Novartis (VTX:NOVN) Is Increasing Its Dividend To $3.50

Feb 04
Novartis (VTX:NOVN) Is Increasing Its Dividend To $3.50

Novartis (VTX:NOVN) Has A Rock Solid Balance Sheet

Dec 17
Novartis (VTX:NOVN) Has A Rock Solid Balance Sheet

We Think Novartis' (VTX:NOVN) Robust Earnings Are Conservative

Nov 05
We Think Novartis' (VTX:NOVN) Robust Earnings Are Conservative

Investors Interested In Novartis AG's (VTX:NOVN) Earnings

Oct 21
Investors Interested In Novartis AG's (VTX:NOVN) Earnings

Novartis (VTX:NOVN) Has A Rock Solid Balance Sheet

Sep 04
Novartis (VTX:NOVN) Has A Rock Solid Balance Sheet

Novartis AG's (VTX:NOVN) Price In Tune With Earnings

Mar 12
Novartis AG's (VTX:NOVN) Price In Tune With Earnings

Novartis (VTX:NOVN) Has Announced A Dividend Of $3.30

Feb 20
Novartis (VTX:NOVN) Has Announced A Dividend Of $3.30

Shareholder Returns

NOVNCH PharmaceuticalsCH Market
7D4.2%4.4%0.1%
1Y11.1%19.2%9.7%

Return vs Industry: NOVN underperformed the Swiss Pharmaceuticals industry which returned 19.2% over the past year.

Return vs Market: NOVN exceeded the Swiss Market which returned 9.7% over the past year.

Price Volatility

Is NOVN's price volatile compared to industry and market?
NOVN volatility
NOVN Average Weekly Movement2.3%
Pharmaceuticals Industry Average Movement2.9%
Market Average Movement3.6%
10% most volatile stocks in CH Market8.3%
10% least volatile stocks in CH Market1.6%

Stable Share Price: NOVN has not had significant price volatility in the past 3 months compared to the Swiss market.

Volatility Over Time: NOVN's weekly volatility (2%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
199675,883Vas Narasimhanwww.novartis.com

Novartis AG engages in the research, development, manufacture, distribution, marketing, and sale of pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still’s disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta.

Novartis AG Fundamentals Summary

How do Novartis's earnings and revenue compare to its market cap?
NOVN fundamental statistics
Market capCHF 194.70b
Earnings (TTM)CHF 10.81b
Revenue (TTM)CHF 46.81b

17.9x

P/E Ratio

4.1x

P/S Ratio

Is NOVN overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NOVN income statement (TTM)
RevenueUS$51.72b
Cost of RevenueUS$12.82b
Gross ProfitUS$38.91b
Other ExpensesUS$26.97b
EarningsUS$11.94b

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

Apr 29, 2025

Earnings per share (EPS)6.05
Gross Margin75.22%
Net Profit Margin23.09%
Debt/Equity Ratio67.1%

How did NOVN perform over the long term?

See historical performance and comparison

Dividends

3.6%

Current Dividend Yield

65%

Payout Ratio

Does NOVN pay a reliable dividends?

See NOVN dividend history and benchmarks
When do you need to buy NOVN by to receive an upcoming dividend?
Novartis dividend dates
Ex Dividend DateMar 11 2025
Dividend Pay DateMar 13 2025
Days until Ex dividend32 days
Days until Dividend pay date34 days

Does NOVN pay a reliable dividends?

See NOVN dividend history and benchmarks

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/06 19:27
End of Day Share Price 2025/02/06 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Novartis AG is covered by 66 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kamla SinghAlphaValue
John EadeArgus Research Company
Fabrizio SpagnaAxia Financial Research